Non-small cell lung cancer is the most common type of lung cancer (80-85%). It is
about 70% are patients with an advanced stage and 50% have mutations in the
epidermal growth factor receptor. EGFR-Tyrosin Kinase Inhibitors (TKIs) are the
first-line therapies used, such as afatinib and erlotinib. Afatinib is better
effectiveness (Progression Free Survival) than erlotinib unfortunately it has higher
price than erlotinib, so it is necessary to do research to improve the quality control
and also cost control in the health services in the era of the JKN so that the selection
and use of these drugs are more effective and efficient. The purpose of this research
was to perform a pharmacacoeconomic analysis of afatinib and erlotinib in NSCLC
patients with EGFR mutations. The unit cost analysis used a retrospective
observational approach and used a cross-sectional study design using a health
provider and patient perspective. In the cost-effectiveness analysis study, using a
cohort design with a pharmaccoeconomic study approach based on an observational
study,with outcome effectiveness in the form of PFS as seen from the patient's
medical record. Utility research is carried out using an approach with a patient
perspective. The ICER value in EGFR mutation NSCLC patients based on the
provider's perspective obtained a value of Rp502.714/month. The ICER value
based on a patient perspective with PFS clinical outcomes was Rp.460.353/month,
while the ICER/QALY value was Rp12.065.148/QALYs. From these two
perspectives the ICER value obtained is smaller than the GDP per capita value of
Rp64.565.462,13.The use of afatinib in NSCLC patients with EGFR mutations has
been shown the increasing of the clinical outcome (PFS) and QALYs and the cost
effective.